{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.363","value":"1.25"},{"groupId":"OG001","spread":"3.324","value":"-2.60"},{"groupId":"OG002","spread":"3.567","value":"2.51"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"64"},{"groupId":"OG002","value":"57"}],"units":"Participants"}],"description":"The Bladder Contractile Index (BCI) is a value used to measure the degree of contractility. BCI was calculated using the following formula:\n\nBCI = pdetQmax + 5Qmax.\n\nStrong contractility is a BCI \\> 150, normal contractility is a BCI of 100-150 and weak contractility is a BCI of \\< 100.\n\nLeast squares means were derived from an ANCOVA model with the pooled study center and treatment as factors and the baseline value as a covariate.","dispersionType":"Standard Error","groups":[{"description":"Participants received matching mirabegron placebo tablets orally once daily for 12 weeks.","id":"OG000","title":"Placebo"},{"description":"Participants received 50 mg mirabegron tablets orally once daily for 12 weeks.","id":"OG001","title":"Mirabegron 50 mg"},{"description":"Participants received 100 mg mirabegron tablets orally once daily for 12 weeks.","id":"OG002","title":"Mirabegron 100 mg"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"The Full Analysis Set included all patients who received at least 1 dose of double-blind study drug \\& had both Qmax \\& PdetQmax measurements at Baseline \\& 1 or both at any postbaseline on-treatment visit. Data include the last on-treatment assessment for patients who did not complete the Week 12 visit.","reportingStatus":"POSTED","timeFrame":"Baseline and Week 12","title":"Change From Baseline to End of Treatment in Bladder Contractile Index (BCI)","type":"SECONDARY","unitOfMeasure":"Scores on a scale"}